Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity (Q34216563)

31 July 2017

1 reference

title

Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity (English)

1 reference

31 July 2017

1 reference

1

Ursula Amstutz

0 references

author name string

Ursula Amstutz

series ordinal

1

1 reference

31 July 2017

Tanja K Froehlich

series ordinal

2

1 reference

31 July 2017

Carlo R Largiadèr

series ordinal

3

1 reference

31 July 2017

publication date

1 September 2011

1 reference

31 July 2017

1 reference

31 July 2017

volume

12

1 reference

31 July 2017

issue

9

1 reference

31 July 2017

page(s)

1321-1336

1 reference

Systemic therapy for colorectal cancer

31 July 2017

cites work

1 reference

Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.

21 January 2018

1 reference

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration

21 January 2018

1 reference

Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene

21 January 2018

1 reference

Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

21 January 2018

1 reference

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase deficiency leading to thymine-uraciluria. An inborn error of pyrimidine metabolism

21 January 2018

1 reference

dbSNP: the NCBI database of genetic variation

21 January 2018

1 reference

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity

21 January 2018

1 reference

Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene

21 January 2018

1 reference

Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity

21 January 2018

1 reference

Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes

21 January 2018

1 reference

Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant

21 January 2018

1 reference

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals

21 January 2018

1 reference

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

21 January 2018

1 reference

A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency

21 January 2018

1 reference

High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity

21 January 2018

1 reference

Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group

21 January 2018

1 reference

Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure

21 January 2018

1 reference

A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms

21 January 2018

1 reference

Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients

21 January 2018

1 reference

The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.

21 January 2018

1 reference

Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity

21 January 2018

1 reference

Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients

21 January 2018

1 reference

Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity

21 January 2018

1 reference

Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemothera

21 January 2018

1 reference

Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population

21 January 2018

1 reference

Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.

21 January 2018

1 reference

CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification

21 January 2018

1 reference

5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case

21 January 2018

1 reference

Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.

21 January 2018

1 reference

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

21 January 2018

1 reference

21 January 2018

Capecitabine: a review

1 reference

Capecitabine-induced multifocal leukoencephalopathy: a report of five cases

21 January 2018

1 reference

A well-tolerated 5-FU-based treatment subsequent to severe capecitabine-induced toxicity in a DPD-deficient patient

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population

21 January 2018

1 reference

Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation

21 January 2018

1 reference

Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma

21 January 2018

1 reference

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients

21 January 2018

1 reference

Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy

21 January 2018

1 reference

Sequence capture and next-generation resequencing of multiple tagged nucleic acid samples for mutation screening of urea cycle disorders

21 January 2018

1 reference

DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model

21 January 2018

1 reference

Keeping up with the next generation: massively parallel sequencing in clinical diagnostics

21 January 2018

1 reference

Next generation sequence analysis for mitochondrial disorders

21 January 2018

1 reference

5-Fluorouracil pharmacogenomics: still rocking after all these years?

21 January 2018

1 reference

Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?

21 January 2018

1 reference

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects

21 January 2018

1 reference

Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function

21 January 2018

1 reference

Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity

21 January 2018

1 reference

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

21 January 2018

1 reference

Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.11.72

1 reference

31 July 2017

1 reference